Biogen Alzheimer's filing likely hit by pandemic, as drugs against the disease set for delay

Biogen has been hinting since the start of the year, with investors also making the same prediction, that a filing with the FDA was “imminent”; we’re now four months down the line, and a major global pandemic appears to have scuppered those plans.